CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BSMOMutationPredictiveSupportsResistanceBasal Cell CarcinomaVismodegib,SonidegibDanial et al., 2016
BNOTCH1MutationPrognosticSupportsPoor OutcomeChronic Lymphocytic LeukemiaOscier et al., 2013
BTP53MutationPredictiveSupportsSensitivity/ResponseChronic Lymphocytic LeukemiaAlemtuzumabLozanski et al., 2004
CALKI1171N AND HIP1::ALK FusionPredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinib,AlectinibOu et al., 2014
CEML4::ALKFusion AND ALK I1171SPredictiveSupportsResistanceLung Non-small Cell CarcinomaAlectinib,CrizotinibOu et al., 2014
BBIRC3TRUNCATING MUTATIONPrognosticSupportsPoor OutcomeChronic Lymphocytic LeukemiaBaliakas et al., 2015
BMYD88L265PPrognosticSupportsBetter OutcomeChronic Lymphocytic LeukemiaBaliakas et al., 2015
DPTENLossPredictiveSupportsResistanceOvarian CancerCisplatinLee et al., 2005
BPTENLossPredictiveSupportsResistanceStomach CarcinomaChemotherapyOki et al., 2005
DEZH2Y646PredictiveSupportsSensitivity/ResponseSkin MelanomaGSK126Tiffen et al., 2015
BCCND1AmplificationPredictiveSupportsSensitivity/ResponseSkin MelanomaCarboplatin,Paclitaxel,SorafenibWilson et al., 2016
BRAF1AmplificationPredictiveSupportsSensitivity/ResponseSkin MelanomaPaclitaxel,Carboplatin,SorafenibWilson et al., 2016
BKRASAmplificationPredictiveSupportsSensitivity/ResponseSkin MelanomaSorafenib,Carboplatin,DocetaxelWilson et al., 2016
DPIK3CAMutationPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerCapivasertibDavies et al., 2012
BCD274ExpressionPredictiveSupportsSensitivity/ResponseCancerNivolumabTopalian et al., 2012
CCTLA4::CD28FusionPredictiveSupportsSensitivity/ResponseSezary's DiseaseIpilimumabSekulic et al., 2015
DNOTCH1Loss-of-functionPredictiveSupportsSensitivity/ResponseHead And Neck Squamous Cell CarcinomaPorcupine Inhibitor WNT974Liu et al., 2013
DCDK6OverexpressionPredictiveSupportsSensitivity/ResponseEstrogen-receptor Positive Breast CancerPalbociclib,FulvestrantAlves et al., 2016
CGNAQQ209PPredictiveSupportsResistanceSkin MelanomaVemurafenibTurajlic et al., 2014
BCCND1OverexpressionPredictiveDoes Not SupportSensitivity/ResponseMantle Cell LymphomaPalbociclibLeonard et al., 2012
BIDH2R140PrognosticDoes Not SupportAcute Myeloid LeukemiaLin et al., 2012
CPIK3CAE542KPredictiveSupportsSensitivity/ResponseHead And Neck Squamous Cell CarcinomaApitolisibDolly et al., 2016
BBRAFD594GPrognosticSupportsPoor OutcomeColorectal CancerAmaki-Takao et al., 2016
DCCND1AmplificationPredictiveDoes Not SupportSensitivity/ResponseRenal Cell CarcinomaPalbociclibLogan et al., 2013
DERBB2AmplificationPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPalbociclib,TrastuzumabFinn et al., 2009
DCCND1AmplificationPredictiveSupportsSensitivity/ResponseBreast CancerPalbociclibFinn et al., 2009
CPPFIBP2::BRAFFusionPredictiveSupportsSensitivity/ResponseSkin MelanomaTrametinibMenzies et al., 2015
BCD274ExpressionPredictiveDoes Not SupportSensitivity/ResponseMerkel Cell CarcinomaPembrolizumabNghiem et al., 2016
BBRAFV600EPredictiveSupportsSensitivity/ResponseHairy Cell LeukemiaVemurafenibTiacci et al., 2015
CKRASG12DPredictiveSupportsResistanceHairy Cell LeukemiaVemurafenibTiacci et al., 2015
CBRAFV600EPredictiveSupportsSensitivity/ResponseColorectal CancerVemurafenib,PanitumumabPietrantonio et al., 2016
DRAD23BEXPRESSIONPredictiveSupportsSensitivity/ResponseSarcomaVorinostatAngelika Ihle et al., 2016
BBRAFV600PredictiveDoes Not SupportSensitivity/ResponseColorectal CancerCetuximab,VemurafenibHyman et al., 2015
CCCDC6::RETFusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaNintedanibTakeda et al., 2016
CFGFR3S249CPredictiveSupportsSensitivity/ResponseTransitional Cell CarcinomaPazopanibPalma et al., 2015
BFGFR1AmplificationPredictiveSupportsSensitivity/ResponseBreast CancerDovitinibAndré et al., 2013
BFGFR2AmplificationPredictiveSupportsSensitivity/ResponseBreast CancerDovitinibAndré et al., 2013
BFGF3AmplificationPredictiveSupportsSensitivity/ResponseBreast CancerDovitinibAndré et al., 2013
DPIK3R1MutationPredictiveSupportsSensitivity/ResponseBreast CancerMTOR Kinase Inhibitor PP242Weigelt et al., 2011
DERBB2AmplificationPredictiveSupportsSensitivity/ResponseBreast CancerMTOR Kinase Inhibitor PP242Weigelt et al., 2011
CSTK11D194EPredictiveSupportsSensitivity/ResponsePancreatic CancerEverolimusKlümpen et al., 2011
CKIF5B::RETFusionPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaEverolimus,VandetanibSubbiah et al., 2015
CPIK3CAH1047RPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerEverolimus,FulvestrantSun et al., 2016
DPTENR130*PredictiveSupportsSensitivity/ResponseThyroid CancerPerifosine,TemsirolimusLiu et al., 2009
EFBXW7Loss-of-functionPredictiveSupportsSensitivity/ResponseRenal Cell CarcinomaEverolimusOkazaki et al., 2014
DRB1M695FS*26PredictiveSupportsResistanceEstrogen-receptor Positive Breast CancerPalbociclibHerrera-Abreu et al., 2016
BFBXW7MutationPredictiveSupportsSensitivity/ResponseCancerMTOR InhibitorJardim et al., 2014
CJUNOverexpressionPredictiveSupportsSensitivity/ResponseColorectal AdenocarcinomaIrbesartanJones et al., 2016
CFOSOverexpressionPredictiveSupportsSensitivity/ResponseColon AdenocarcinomaIrbesartanJones et al., 2016
BMDM2RS34886328PrognosticSupportsBetter OutcomeEsophagus Squamous Cell CarcinomaLi et al., 2016
Page 72 of 96
PreviousNext